Daiichi Sankyo Company, Limited (4568) Press Release
(Modification of Disclosed Matter) Notice Regarding Change in the Effective Date of the Absorption-type Merger of Daiichi Sankyo with Its Wholly Owned
Earlier from Daiichi Sankyo
- DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
- Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio